3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Thyroid Neoplasms
2
Brain Neoplasms
2
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Interventions
Cisplatin
30
Radiotherapy
24
pembrolizumab
21
Cetuximab
21
Docetaxel
13
Fluorouracil
12
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Radiation
8
Nivolumab
7
Everolimus
7
Carboplatin
7
Oxaliplatin
6
Gemcitabine
5
Surgical Procedures, Operative
4
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
Gefitinib
4
Erlotinib Hydrochloride
4
Amifostine
4
Pemetrexed
3
Filgrastim
3
Capecitabine
3
Bleomycin
3
Biopsy
3
zalutumumab
2
spartalizumab
2
pegfilgrastim
2
niraparib
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Head and Neck Neoplasms
×
alectinib
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts